Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease

Key Points

• This research aims to assess the safety and effectiveness of weekly 80 mg adalimumab therapy in children with Crohn's disease.
• Evaluated pediatric patients experiencing pharmacokinetic loss of response to current treatments.
• Administered weekly doses of 80 mg adalimumab.
• Monitored patient outcomes regarding safety and therapeutic efficacy.
• 80 mg weekly adalimumab demonstrated an effective response in pediatric patients.
• Treatment was well-tolerated with minimal adverse effects noted.
• Findings suggest a potential benefit in intensification of therapy.